Lisa Anson, chief executive of (), caught up with Proactive London's Andrew Scott to discuss the group's preliminary results to September 2018 as well as the appointment of a new chief financial officer.
Anson says Redx is ready to begin first-in-man trials of lead oncology drug, RXC004, in the first half of next year.
Putative fibrosis treatment RXC006 is expected to enter the clinic the year after.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Redx Pharma Plc named herein, including the promotion by the Company of Redx Pharma Plc in any Content on the Site, the Company receives from...
FOR OUR FULL DISCLAIMER CLICK HERE